Fourth Quarter and Year-End 2025 Financial Results & Business Update February 25, 2026 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results an. ...

In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.43 per share, reflecting a decline of 58.7% compared to the same period last year. Revenues are forecasted to be $379.96 million, representing a year-over-year decrease of 11.6%.The consensus EPS estimate for the quarter has been revised 152.2% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Gold: Like Treasury bonds, gold saw solid buying on Monday as investors continued to add to safe-haven positions. The bullion finished Monday's trading at $5,227, up 2.38%. Worries over the Middle East, plus UBS raising its target price for Gold to $6,200 by the middle of 2026, added to the tailwind that was already pushing the commodity higher. Silver was the big winner Monday, closing up 4.23% at $88.10. Crypto: Cryptocurrency prices fell sharply early on Monday, with Bitcoin dropping 3% to 5% over the co ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Considering buying SO stock? Here’s what analysts think: Photo via Shutterstock ...

Group 1 - Alkermes (ALKS) is currently performing well in the Medical sector, with a year-to-date gain of approximately 21.1%, significantly outperforming the average gain of 6.3% for Medical stocks [4] - The Zacks Rank for Alkermes is 1 (Strong Buy), indicating strong analyst sentiment and a positive earnings outlook, with a 9% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Alkermes belongs to the Medical - Biomedical and Genetics industry, which includes 450 stocks and is currently ranked 94 in the Zacks Industry Rank, with an average gain of 20.5% year-to-date [5] Group 2 - CASI Pharmaceuticals Inc. is another Medical stock that has outperformed the sector, with a year-to-date return of 20% and a Zacks Rank of 2 (Buy) [4][5] - The Medical - Drugs industry, to which CASI Pharmaceuticals belongs, is ranked 154 and has seen a modest gain of 2.1% this year [6] - Investors in the Medical sector should monitor both Alkermes and CASI Pharmaceuticals for their strong performance trends [6]

Company Overview - Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and selling medicines for schizophrenia, bipolar I disorder, and addiction to alcohol or opioids [2]. Recent Developments - On January 6, Alkermes announced that the FDA granted Breakthrough Therapy designation to its alixorexton therapy for narcolepsy type 1, following positive results from phase 1 and phase 2 studies [2]. - The clinical trial involved 92 patients and demonstrated that the oral orexin 2 receptor agonist achieved its primary endpoint, showing statistically significant, dose-dependent improvements in wakefulness [2]. - Craig Hopkinson, M.D., emphasized that alixorexton could significantly improve treatment for narcolepsy type 1, addressing unmet medical needs in the community [2]. - The company plans to advance alixorexton into phase 3 development later this quarter [2]. Market Sentiment - Jim Cramer expressed skepticism about Alkermes, suggesting it is a hold, possibly a weak one, indicating a lack of strong recommendation for the stock [1].

Core Insights - Alkermes (ALKS) has a strong track record of exceeding earnings estimates, particularly in the last two quarters, with an average surprise of 21.75% [1][5] - The company reported earnings of $0.49 per share for the last quarter, surpassing the Zacks Consensus Estimate of $0.42 per share by 16.67% [2] - In the previous quarter, Alkermes achieved earnings of $0.52 per share against an expectation of $0.41 per share, resulting in a surprise of 26.83% [2] Earnings Estimates and Predictions - Recent changes in earnings estimates for Alkermes have been favorable, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8] - The current Earnings ESP for Alkermes is +11.29%, suggesting that analysts are optimistic about the company's earnings prospects [8] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] Zacks Rank and Earnings ESP - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A positive Earnings ESP combined with a Zacks Rank of 1 (Strong Buy) indicates a high probability of another earnings beat for Alkermes [8] - It is crucial to check a company's Earnings ESP before quarterly releases to enhance the likelihood of successful investment decisions [9]

Group 1: Guess, Inc. (GES) - Guess, Inc. is a lifestyle and apparel company with a Zacks Rank of 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 5.6% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 9.93, significantly lower than the industry average of 24.40 [1] - Guess possesses a Value Score of B [1] Group 2: National Energy Services Reunited Corp. (NESR) - National Energy Services Reunited Corp. is an oilfield services company with a Zacks Rank of 1 [2] - The Zacks Consensus Estimate for its next year earnings has increased by 4.1% over the last 60 days [2] - The company has a price-to-earnings ratio (P/E) of 11.85, compared to the industry average of 21.60 [2] - NESR possesses a Value Score of A [2] Group 3: Alkermes plc (ALKS) - Alkermes plc is a biopharmaceutical company with a Zacks Rank of 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 3.1% over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 19.23, lower than the S&P average of 25.72 [3] - Alkermes possesses a Value Score of A [3]

Core Insights - Alkermes is positioned for growth in 2026, building on accomplishments from 2025 to enhance its value creation potential [3][5] - The company is characterized as a profitable neuroscience firm with a late-stage candidate, indicating a strong foundation for future development [5] Company Overview - Alkermes is participating in the 44th Annual Healthcare Conference, showcasing its management team and strategic direction [2] - The CEO, Richard Pops, expressed excitement about the company's trajectory and future opportunities [3] Financial and Strategic Position - The company emphasizes its strong foundation for both near-term and long-term growth, highlighting its profitability and leadership in the neuroscience sector [5]